Selection of topics for the HTA program

The FOPH has launched a public procedure for submitting topics for the health technology assessment (HTA) program. Interested bodies and individuals can use a submission form to submit topics on an annual basis. The FOPH will also propose topics.

Procedure

The deadline for submitting topics is the end of October each year (From 2019 on, this deadline will be the 1st of March).

A range of predefined criteria will be used to prioritise the topics submitted according to their clinical significance and potential for reducing costs. All topics will be assessed and prioritised both within the FOPH and by the relevant stakeholders.

As of 2018, HTA topics are selected either for a full HTA report or for a short report. The nature of the evidence base of a topic directs the choice between a full or a short report. Full reports follow a systematic and detailed assessment procedure addressing various aspects of a health technology. Short reports vary in terms of retrieval, examination and assessment methods of the evidence. Short reports typically take less time, include limited sources with language and time restrictions, present narrative summaries only and may incorporate existing evidence syntheses.

Topics 2019

Selected topics 2019

  • Medicines for Alzheimer's disease/dementia
  • Infliximab biosimilars in rheumatoid arthritis
  • Palbociclib for HR+/HER2- advanced breast cancer
  • Denosumab in osteoporosis
  • Sedatives and sleeping pills for anxiety and sleep disorders
  • Vitamin B12 testing for suspected vitamin B12 deficiency
  • Levothyroxine in elderly patients with subclinical hypothyroidism
  • Folic acid tests for suspected folic acid deficiency
  • Thyroid hormone tests for the diagnosis of primary hypo- or hyperthyroidism
  • Long-term physiotherapy for multiple sclerosis / Parkinson's disease / Hemiplegia
  • Dosage interval of zoledronate in bone metastases of solid tumors and in multiple myeloma

Topics 2018

Selected topics 2018

For a review by means of a full HTA, the following topics were selected:

  • Cholesterol-lowering agents
  • The treatment of primary hypercholesterolemia with ezetimibe-containing medicines
  • Surgical treatment of osteoporotic vertebral body fractures by vertebroplasty and kyphoplasty
  • Surgical intervention in shoulder impingement syndrome

For a review by means of a short report or contextualization of an existing HTA report, the following topics were selected:

  • Glitazones in type 2 diabetes
  • Glinides in type 2 diabetes
  • Dual platelet inhibition following coronary implantation of drug-coated stents

Topics 2017

Selected topics, 2017

  • Mono and combination therapies with olmesartan
  • Vitamin D tests
  • Proton-pump inhibitors (PPIs) for patients with non-erosive gastro-oesophageal reflux disease and non-endoscopic reflux disease

Topics 2016

Selected topics 2016

  • Self-monitoring of blood glucose for patients with non-insulin-dependent (Type 2) diabetes
  • Use of drugs containing chondroitin sulphate in the treatment of joint arthrosis
  • Removal of osteosynthesis devices (e.g. screws, plates, nails and wires) used to treat bone fractures

Topics 2015

Topics determined directly by the EDI, 2015

  • Knee arthroscopy
  • Spinal procedures involving different implants
  • Iron substitutes for iron deficiency without anaemia

Last modification 28.11.2019

Top of page

Contact

Federal Office of Public Health FOPH
Division of Health Care Services
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Berne
Switzerland
Tel. +41 58 462 21 11
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-bezeichnung-der-leistungen/re-evaluation-hta/themenwah-hta-programm.html